Slide 1: Financial Results for FY2020
Financial Results for FY2020 Ended March 31, 2021 ～ For Healthy and Affluent Lives of People Around The World ～ http://www.transgenic.co.jp May 26, 2021 TRANS GENIC INC. Note: This material includes forward-looking statements based on assumptions and beliefs in light of the information currently ava
Slide 2: Table of Contents
Table of Contents Ⅰ. Consolidated Financial Results Summary for FY2020 Ⅱ. Consolidated Business Forecast for FY2021 Ⅲ. About TransGenic Group Ⅳ. Current Status of Research and Development Copyright© TransGenic Inc. All Rights Reserved. 1
Slide 3: Consolidated Financial Results Summary for FY2020
Ⅰ. Consolidated Financial Results Summary for FY2020 Copyright© TransGenic Inc. All Rights Reserved. 2
Slide 4: Consolidated Financial Results Highlight of FY2020
Overview of Consolidated Financial Results Consolidated Financial Results Highlight of FY2020 Consolidated sales amount totaled 11,046 million yen (almost the same as FY2019), but gross operating income increased to 2,777 million yen (up 997 million yen) due to increased gross profit in drug disco
Slide 5: Consolidated Financial Results for FY2020: Sales Amount
Overview of Consolidated Financial Results Consolidated Financial Results for FY2020: Sales Amount Change of consolidated sales amount （million yen） 12,000 Consolidated sales amount Drug discovery totaled 11,046 million yen support (almost the same as FY2019) TGBS 10,000 ・TGBS business was struggled
Slide 6: Consolidated Operating Profit/Loss
Overview of Consolidated Financial Results Consolidated Financial Results of 2Q-FY2020: Operating Profit/Loss Change of consolidated Consolidated operating profit （million yen） operating profit/loss 1,150 reached a record high of TGBS 893 million yen (up 719 million yen from FY2019) Drug discovery 3
Slide 7: Consolidated Financial Results of FY2020: Recurring Profit
Overview of Consolidated Financial Results Consolidated Financial Results of FY2020: Recurring Profit Change of consolidated （million yen） recurring profit 1,000 Consolidated recurring profit totaled 800 891 891 million yen (the highest-ever level, up 796 million yen from FY2019) 600 in association
Slide 8: Net profit attributable to shareholders of parent company
Overview of Consolidated Financial Results Consolidated Financial Results of FY2020: Net profit attributable to shareholders of parent company Change of net profit attributable to （million yen）shareholders of parent company 800 600 Net profit attributable to shareholders of parent 546 company showed
Slide 9: Cash Flow from Operating Activities (CFO)
Overview of Consolidated Financial Results Consolidated Financial Results of FY2020： Cash Flow from Operating Activities (CFO) （million yen） Change of CFO 1,300 CF EBITDA ※ 1,222 Consolidated CFO climbed to 1,100 all-time high of 1,222 million yen (up 1,243 million yen from 900 FY2019) due to signif
Slide 10: Performance summary: Drug Discovery Support Business
Overview of Sales Revenue Performance summary: Drug Discovery Support Business （change in 5 years） Sales amount increased to 3583 million yen (1.5 times), operating profit increased to 745 million yen (more than double) in 4 years （million yen） Sales amount and operating profit are growing consist
Slide 11: Performance summary: TGBS business
Overview of Sales Revenue –TGBS Business Performance summary: TGBS business（change in 4 years） TGBS business grew with sales amount of 7000 ～ 8000 million yen and operating profit of more than 300 million yen in 4 years （million yen） Both sales amount and operating profit grew consistently since t
Slide 12: Consolidated Business Forecast for FY2021
Ⅱ. Consolidated Business Forecast for FY2021 Copyright© TransGenic Inc. All Rights Reserved. 11
Slide 13: Consolidated Business Forecast for FY2021
Consolidated Business Forecast for FY2021 Sales and profit are expected to increase in the light of strong performance of drug discovery support business Tax burden including corporate tax will increase as loss carried forward was eliminated on March 2021, therefore increase of net profit is giv
Slide 14: Consolidated Business Forecast for FY2021: by Business Segment
Consolidated Business Forecast for FY2021: by Business Segment PCR testing service in drug discovery support business is anticipated to lead consolidated operating profit of FY2021 If COVID-19 continues to spread, general consumption and capital spending plan of companies are presumed to shrink,
Slide 15: PCR testing Service for COVID-19
Consolidated Business Forecast for FY2021 PCR testing Service for COVID-19 Number of COVID-19 positive in Hokkaido was on the decrease in January and February, 2021, but after that, the number is increasing especially from the end of April. Accordingly, number of PCR testing in GeneticLab is inc
Slide 16: About TransGenic Group
Ⅲ. About TransGenic Group Copyright© TransGenic Inc. All Rights Reserved. 15
Slide 17: Business Summary of TransGenic Group
Business Summary of TransGenic Group TransGenic Group will achieve sustained growth by hybrid-type business consisting of “Drug discovery support business” providing seamless support including basic research, clinical studies, and diagnosis based on leading-edge biotechnology, and “TGBS business “co
Slide 18: Progress Report of Management Reform
Progress Report of Management Reform Management reform of TransGenic Group has been moved forward with a phased approach (by 4 years) Next stage（Stage Ⅳ）will also be implemented for 4 years (FY2021 to FY2024) Reference（previous reform goals and results） (Unit: million yen) Stage Period Goal of r
Slide 19: Positioning of Next Four Years (FY2021-2024)
Positioning of Next Four Years（FY2021～2024） TransGenic Inc. became pure holding company on April 1, 2021. Vision Under the new management structure, we define next Corporate philosophy four years as the term to implement priority To strive toward future development as well as measures consistently t
Slide 20: Priority measures to Reinforce Business Foundation
Priority measures to Reinforce Business Foundation Capital investment（drug discovery support business） About 150 million yen for PCR testing devices in order to enhance COVID-19 testing capability About 200 million yen for LCMS device to enhance non-clinical testing service, CT apparatus and E
Slide 21: Transfer of Genetic Modified Mouse Business to BSRC
Priority measures to Reinforce Business Foundation：Construction of Highly Profitable Business Entity Transfer of Genetic Modified Mouse Business to BSRC Development of high-value added service by internal reorganization in order to construct highly profitable entity （Until FY2020） （From FY2021） Main
Slide 22: Transfer of Antibody Business to Medicinal Chemistry Pharmaceutical
Priority measures to Reinforce Business Foundation：Construction of Highly Profitable Business Entity Transfer of Antibody Business to Medicinal Chemistry Pharmaceutical Co., Ltd. Strengthening and accelerating the development/discovery of antibody drug by internal reorganization in order to construc
Slide 23: Promotion of TGBS Business (M&A)
Priority measures to Reinforce Business Foundation Promotion of TGBS Business (M&A) Investment for TGBS business（M&A）will be promoted responding to operating revenue according to investment principle Niche Steady marketing Autonomous Investment （million yen） surplus （with unique management principle
Slide 24: Current Status of Research and Development
Ⅳ. Current Status of Research and Development Copyright© TransGenic Inc. All Rights Reserved. 23
Slide 25: Introduction and Development Status of Mouse Model Strains
Overview of Research & Development Pipeline Introduction and Development Status of Mouse Model Strains Approx. 2 years Approx. 2 years Development of mouse model strains Target Phenotype Distribution *In-house Development or Technological introduction KO or Tg Validation from external research insti
Slide 26: Mouse Model Strains: Humanized Mouse
Overview of Research & Development Pipeline Introduction and Development Status of Mouse Model Strains Approx. 2 years Approx. 2 years Development of mouse model strains Target Phenotype Distribution *In-house Development or Technological introduction KO or Tg Validation from external research insti
Slide 27: Status of the Development Pipeline: Antibody/Diagnostic/Therapeutic Agent
Overview of Research & Development Pipeline Status of the Development Pipeline: Antibody/ Diagnostic Agent/ Therapeutic Agent Approx. 3 years Approx. 2 years～ Target Antibody Utility Assay system Licensing& Launching onto Clinical identification production verification establishment development the
Slide 28: Development of Anti-SARS-CoV-2 Spike Protein Antibodies
Overview of Research & Development Pipeline Development of Anti-SARS-CoV-2 Spike Protein Antibodies ◆Overview of the development of anti-SARS-CoV-2 spike protein※ antibodies We succeeded in obtaining antibodies binding to “glycosylation site” of spike protein on the surface of novel coronavirus, and
Slide 29: ～ For Healthy and Affluent Lives of People Around The World ～ http://www.transgenic.co.jp
～ For Healthy and Affluent Lives of People Around The World ～ http://www.transgenic.co.jp Copyright© TransGenic Inc. All Rights Reserved. 28